Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29871710 | 0.96 | CTSL (0.53) | NPBWR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30063985 | 0.95 | GLP1R (0.54) | NPBWR1CTSLCTSSCTSKGLP1R | |
| SCHEMBL30183034 | 0.95 | GLP1R (0.55) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL29484313 | 0.94 | NPBWR1 (0.55) | NPBWR1CTSLCTSSCTSKCTSH | |
| SCHEMBL29484310 | 0.93 | CTSL (0.53) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL30216222 | 0.91 | GLP1R (0.52) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL30064553 | 0.90 | GLP1R (0.58) | GLP1R | |
| SCHEMBL30208638 | 0.90 | GLP1R (0.57) | GLP1RCXCR4GCGR | |
| SCHEMBL29489380 | 0.89 | CTSL (0.53) | NPBWR1CTSLCTSSCTSKCTSH | |
| SCHEMBL29484311 | 0.89 | GLP1R (0.56) | CTSLCTSSCTSKCTSHGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | SIXTH STREET LENDING PARTNERS | 2024-03-07 | — | — | US | disclosed |
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3996744-A1 | VIRAL VECTOR THERAPY | Apellis Pharmaceuticals, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | C3AR1, C5AR1, SERPINC1 | NPBWR1 803/4885CTSL 10/4885CTSS 56/4885 |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | C3AR1, C5, CFH | NPBWR1 1496/4885CTSL 43/4885CTSS 178/4885 |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | C3AR1, C5AR1, SERPINC1 | NPBWR1 803/4885CTSL 10/4885CTSS 56/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | NPBWR1 555/4885CTSL 7/4885CTSS 58/4885 |
| US-20220249706-A1 | VIRAL VECTOR THERAPY | CFH, CFB, HAVCR2 | NPBWR1 1371/4885CTSL 761/4885CTSS 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.